Rhythm Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-196.54	-260.6	-184.68	-181.12	-69.61
Depreciation & Amortization	1.34	1.56	1.76	1.67	1.16
Loss (Gain) From Sale of Investments	-6.52	-8.17	-9.84	-1.27	-
Stock-Based Compensation	66.82	39.68	32.55	19.83	20.8
Other Operating Activities	20.19	103.07	19.24	4.87	-100.25
Change in Accounts Receivable	-7.57	-3.65	-8.64	-5.2	-1.25
Change in Inventory	-7.47	-10.12	-5.71	-2.81	-0.01
Change in Accounts Payable	21.89	21.92	14.77	1.54	18.31
Change in Unearned Revenue	-1.09	-	-0.15	-6.61	-
Change in Other Net Operating Assets	-6.72	2.42	4.53	-4.34	-15.15
Operating Cash Flow	-115.68	-113.88	-136.16	-173.43	-146
Capital Expenditures	-0.95	-	-0.05	-0.28	-0.43
Sale (Purchase) of Intangibles	-40	-40.5	-5.67	-	7
Investment in Securities	-96.2	-7.67	0.05	32.31	-163.73
Other Investing Activities	-	-	-	-4	95
Investing Cash Flow	-137.15	-48.17	-5.67	28.03	-62.16
Issuance of Common Stock	237.88	56.39	57.4	141.49	166.48
Other Financing Activities	-19.92	-4	16.97	72.34	-
Financing Cash Flow	217.96	191.24	74.37	213.83	166.48
Foreign Exchange Rate Adjustments	0.09	0	-0.14	-	-
Net Cash Flow	-34.78	29.19	-67.6	68.43	-41.68
Free Cash Flow	-116.63	-113.88	-136.2	-173.71	-146.44
Free Cash Flow Margin	-61.46%	-87.51%	-175.91%	-734.87%	-4642.90%
Free Cash Flow Per Share	-1.79	-1.87	-2.36	-3.33	-2.95
Levered Free Cash Flow	-145.98	-81.99	-91.47	-105.11	-57.05
Unlevered Free Cash Flow	-133.12	-69.11	-82.79	-101.86	-57.05
Change in Working Capital	-0.97	10.58	4.81	-17.41	1.9

Source: S&P Global Market Intelligence. Standard template. Financial Sources.